aTyr Pharma, Inc. (LIFE) stock experiences a sudden increase of 19.23% in the aftermarket because the company announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose-Response for ATYR1923 in Pulmonary Sarcoidosis. However, the last trading session closed at $9.15 with an incline of 66.97%.
Positive Data from Phase 1b/2a Clinical Trial
aTyr Pharma, Inc. (LIFE) stock Announces Positive Data from Phase 1b/2a Clinical Trial on 13th September 2021. ATYR1923 received encouraging results from a Phase 1b/2a.
Moreover, at all dosages, ATYR1923 was shown to be safe and well-tolerated, with no drug-related severe adverse events or signs of immunogenicity. Furthermore, the study found that ATYR1923 had a consistent dosage response on key effectiveness endpoints. It also showed benefits when compared to placebo, including steroid reduction, lung function, sarcoidosis symptom assessments, and inflammatory biomarkers.
Second Quarter 2021 Financial Results
aTyr Pharma, Inc. (LIFE) stock reported second-quarter 2021 financial and corporate results on August 10, 2021. As of June 30, 2021, the company has $44.1 million in cash, cash equivalents, and investments.
Moreover, for the second quarter of 2021, research and development expenses totaled $7.7 million, largely due to program costs for ATYR1923 and ATYR2810.
In the second quarter of 2021, general and administrative expenses were $2.8 million. Lastly, as of August 9, 2021, there were 16,919,872 common shares outstanding.
LIFE Stock Announces Expansion of Research Collaboration with The Ohio State University
On 10th August 2021, LIFE stock revealed that the company has expanded its joint effort with The Ohio State University. This will help comprehend the immune mechanisms of sarcoid granuloma formation and identify possible biomarkers of efficacy for ATYR1923. The company’s lead therapeutic candidate for the treatment of pulmonary sarcoidosis is currently under clinical development.
Firstly, Professor of Pulmonology, Critical Care, and Sleep Medicine Elliott Crouser, M.D., will lead the study. Dr. Crouser, a sarcoidosis expert, will lead the study as the primary investigator.
Secondly, the partnership will evaluate the effect of ATYR1923 on sarcoid granuloma development in vitro in blood samples collected from sarcoidosis patients.
Thirdly, the goal of the study is to discover the immunological processes involved in granuloma development. Last but not the least, the study is also done to determine if potential biomarkers indicative of robust granuloma formation may be employed as predictive biomarkers for treatment selection or response to ATYR1923.
LIFE Stock Announces Grant of U.S. Patent
LIFE stock reported on 29 July 2021 that the United States Patent and Trademark Office has awarded a patent covering techniques. These techniques will help decrease inflammatory response in the lungs using histidyl-tRNA synthetase Fc fusion proteins. The patent, entitled “Histidyl-tRNA synthetase-FC conjugates,” addresses the use of ATYR1923 to reduce the inflammatory responses in the lungs.
Last but not the least, ATYR1923 is an Fc fusion protein based on the N terminal segment of histidyl-tRNA synthetase that is being tested in various inflammatory lung disorders and is now in clinical development for the treatment of pulmonary sarcoidosis.